Seattle Startup Archon Biosciences Secures $20 Million to Revolutionize Cancer Treatment with Innovative Protein Technology
A Seattle-based biotechnology startup has emerged from stealth mode, announcing $20 million in seed funding to advance its innovative protein-based therapeutic technology. Archon Biosciences, a spinoff from the University of Washington’s Institute for Protein Design, is developing what it calls “Antibody Cages” (AbCs) – novel protein structures designed to deliver targeted treatments for cancer and other diseases.
The funding round was spearheaded by Madrona Ventures, with additional backing from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments, and Cornucopian Capital.
The company’s emergence comes on the heels of UW biochemist David Baker’s Nobel Prize win, validating the field of computational protein design that underpins Archon’s technology. Baker, who serves as a co-founder, helped establish the foundation for the company’s innovative approach.
The AbC technology combines natural antibodies with custom-designed proteins to create unified structures that can be precisely controlled within the body. Using generative AI, these structures are optimized for specific cellular targeting while minimizing unwanted effects on healthy tissue.
“How a drug behaves is actually incredibly important,” explains James Lazarovits, CEO and co-founder of Archon. The company’s modular design approach allows for rapid iteration and optimization, similar to how automotive manufacturers use shared platforms to create different vehicle models efficiently.
The 17-person company has already begun animal testing of their AbCs, with promising early results. According to Lazarovits, they have demonstrated superiority over a previous clinical molecule that failed in Phase II trials, suggesting the platform’s potential to overcome historical therapeutic limitations.
Archon’s journey to commercialization began with substantial academic support, having secured over $7 million in grants before seeking private investment. The technology was first detailed in a 2021 Science publication, after which George Ueda, now Chief Technology Officer, was encouraged by Baker to pursue commercial development.
The company can produce new AbCs every eight minutes and is focusing initially on cancer treatment applications. “We can either make a cancer cell die a lot, die a little bit, be neutral, or target an immune cell that fights the cancer and turn that up,” Ueda explained.
Chris Picardo, partner at Madrona Ventures and Archon board member, described the AbC approach as “revolutionary,” praising the company’s ability to create new preclinical molecules with exceptional speed and precision.
The fresh funding is expected to support Archon’s development over the next 18 months, during which time the company aims to clearly define its lead programs for clinical development. The startup has licensed its technology from the University of Washington and follows in the footsteps of other successful spinouts from the Institute for Protein Design.
Lazarovits emphasized that while specific program details remain under wraps, the company is well-positioned to integrate its technology into established therapeutic frameworks. The modular nature of their platform allows them to pursue multiple drug development paths simultaneously, potentially accelerating the timeline from conception to clinical application.
The technology’s development represents a convergence of multiple scientific fields, enabled by recent advances in computational biology and artificial intelligence. As Lazarovits noted, “You could not do anything that we’re doing unless there was the convergence of all these different fields at this moment in time.”
